Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Should You Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $15.22, but opened at $16.30. Ono Pharmaceutical shares last traded at $16.30, with a volume of 300 shares changing hands.

Ono Pharmaceutical Price Performance

The firm has a 50-day moving average of $14.13 and a 200-day moving average of $12.49. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02. The firm has a market capitalization of $8.77 billion, a P/E ratio of 20.98 and a beta of 0.25.

Ono Pharmaceutical (OTCMKTS:OPHLF) last posted its earnings results on Monday, February 2nd. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.11. The business had revenue of $892.70 million during the quarter, compared to analyst estimates of $727.58 million. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.